AZN Astrazeneca PLC

39.15
-0.09  -0%
Previous Close 39.24
Open 39.2
Price To Book 8.31
Market Cap 99191356345
Shares 2,533,623,406
Volume 4,628,340
Short Ratio 4.52
Av. Daily Volume 4,832,056

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b/2 trial initiation announced April 16, 2018.
Tagrisso and G1T38
EGFR mutation-positive non-small cell lung cancer (NSCLC)
Phase 3 data due 2020.
Tezepelumab - NAVIGATOR
Asthma
Expanded approval announced August 28, 2017.
Faslodex (fulvestrant)
Monotherapy for expanded use in women with HR+, HER2- advanced breast cancer
Phase 3 completion of enrollment announced June 7, 2018 with data due 4Q 2018. Pooled MACE safety data 1H 2019.
Roxadustat - ANDES
Anaemia in Chronic Kidney Disease
Phase 3 data due 2020.
Farxiga (Dapa-CKD)
Chronic Kidney Disease
Phase 3 data met one of two primary endpoints - 3Q 2018.
Farxiga - DECLARE
Type-2 diabetes
Phase 1b/2a enrolling.
MEDI0457
HPV-associated squamous cell carcinoma of the head & neck (SCCHN)
Phase 3 data released November 1, 2017 - primary endpoint not met.
Tralokinumab (STRATOS2)
Severe, uncontrolled asthma
Phase 3 data due 2020.
Farxiga (Dapa-HF)
Heart failure
Phase 3 data released May 30, 2018. Primary endpoint not met.
Benralizumab - TERRANOVA
COPD
Approval announced March 31, 2017.
Tagrisso
Epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC)
Phase 3 data due 2020.
Durvalumab (ADJUVANT)
Adjuvant Non-small cell lung cancer (NSCLC)
Phase 3 trial did not meet primary endpoint - May 10, 2017.
Tralokinumab (STRATOS1)
Severe, uncontrolled asthma
Phase 3 trial did not meet primary endpoint - noted July 26, 2018.
Selumetinib - ASTRA
Thyroid cancer
Approval announced April 19, 2018.
Tagrisso - FLAURA
First-line lung cancer
Phase 3 data due 2H 2019.
PT010
Chronic obstructive pulmonary disease (COPD)
FDA approval announced September 13, 2018.
Moxetumomab
Cancer - leukaemia
PDUFA date under priority review 1Q 2019.
Lynparza - SOLO 1
First-line ovarian cancer following platinum-based chemotherapy
Approval announced August 17, 2017.
Lynparza - SOLO 2
Second-line ovarian cancer
Phase 3 data released February 17, 2016 - primary endpoint met. Late breaker at ASCO June 4, 2017 showed HR of 0.58 (42% reduction of risk of disease progression or death). Approval announced January 12, 2018.
Lynparza
Breast cancer
Phase 3 data released July 27, 2017 - primary endpoint (PFS) not met. Overall survival data also did not meet primary endpoint - November 16, 2018.
Durvalumab +/- tremelimumab (MYSTIC)
Lung cancer
Phase 3 data due 1H 2019.
Durvalumab +/- tremelimumab (NEPTUNE)
Lung cancer
Phase 3 data 1H 2019.
Durvalumab +/- tremelimumab (KESTREL)
Head & neck cancer
Phase 3 data due 2H 2019.
Durvalumab +/- tremelimumab (DANUBE)
Bladder cancer
Phase 3 data released December 7, 2018 - primary endpoints not met.
Durvalumab +/- tremelimumab (EAGLE)
Head & neck cancer
Phase 3 data released April 24, 2018 - primary endpoints not met.
Durvalumab +/- tremelimumab (ARCTIC)
Non-small cell lung cancer (NSCLC)
Approval announced February 19, 2018.
Durvalumab (PACIFIC)
Lung cancer
Phase 3 Cardiovascular Outcome trial data released September 14, 2017 - primary efficacy objective of a superior reduction in MACE missed statistical significance (p=0.061).
Bydureon
Type 2 Diabetes
Phase 3 data due 1H 2019.
Brilinta (THEMIS)
Type 2 Diabetes
Phase 3 TULIP 1 data released August 31, 2018. Primary endpoint not met. TULIP 2 data are due later in 2018.
Anifrolumab
Lupus
Priority Review announced August 2, 2017. Approval announced October 31, 2017.
Acalabrutinib
Relapsed or Refractory Mantle Cell Lymphoma
BLA acceptance announced December 9, 2017. PDUFA under priority review. Approval announced May 1, 2017.
Urothelial carcinoma - Bladder cancer
Bladder cancer
Second CRL issued March 17, 2017. Approval announced May 18, 2018.
Lokelma (ZS-9)
Hyperkalaemia
Approval announced February 28, 2017.
Saxagliptin and dapagliflozin
Type-2 diabetes
Approval announced November 14, 2017.
Benralizumab
Severe, uncontrolled asthma
Announced discontinuation of trial due to futility - June 12, 2018.
Lanabecestat (AZD3293) - AMARANTH
Early Alzheimer's disease
Phase 3 data due 2019.
Lynparza - SOLO 3
Third-line ovarian cancer
Phase 3 data due 1H 2019.
Lynparza
Pancreatic cancer
Phase 3 data due 2H 2019.
Imfinzi + tremelimumab (POSEIDON)
Non-small cell lung cancer (NSCLC)
Phase 3 data due 2H 2019.
Imfinzi + tremelimumab (CASPIAN)
Small cell lung cancer (SCLC)
Phase 3 data due 2020.
Lynparza - OlympiA
HER2-negative breast cancer
Phase 3 trial did not meet primary endpoint - noted May 11, 2018.
Fasenra (benralizumab) - GALATHEA
Chronic obstructive pulmonary disease (COPD)
Phase 3 data due 2H 2019.
Lynparza
Castration-Resistant Prostate Cancer
Phase 3 data due 2H 2019.
Calquence
Chronic lymphocytic leukaemia
Phase 3 data due 2H 2019.
Lynparza + Avastin- PAOLA-1
First-line ovarian cancer
Phase 1b/2 data presented at ESMO 2018. 23% PR/CR.
Durvalumab Plus Danvatirsen
Refractory head and neck cancer
Phase 3 final OS data due 2H 2019.
Tagrisso - FLAURA
Non-small cell lung cancer (NSCLC)
Phase 3 data due 2020.
Brilinta (THALES)
Acute ischaemic stroke
Phase 1a interim data due mid-2019.
ABI-H2158
Hepatitis B virus (HBV)